Zacks Research Issues Optimistic Estimate for JAZZ Earnings

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) - Stock analysts at Zacks Research boosted their Q1 2025 earnings per share estimates for Jazz Pharmaceuticals in a note issued to investors on Tuesday, April 29th. Zacks Research analyst S. Ganoria now expects that the specialty pharmaceutical company will earn $3.52 per share for the quarter, up from their previous estimate of $3.51. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals' Q2 2026 earnings at $4.75 EPS, Q3 2026 earnings at $5.78 EPS, Q4 2026 earnings at $5.85 EPS, FY2026 earnings at $19.49 EPS, Q1 2027 earnings at $3.34 EPS and FY2027 earnings at $20.54 EPS.

A number of other research analysts have also recently weighed in on JAZZ. Piper Sandler reissued an "overweight" rating and set a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Needham & Company LLC reissued a "buy" rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, April 10th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Barclays reaffirmed an "overweight" rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Finally, Truist Financial upped their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $187.71.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock traded down $1.86 on Thursday, hitting $118.19. The company's stock had a trading volume of 1,276,826 shares, compared to its average volume of 806,745. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a fifty day moving average price of $122.63 and a 200-day moving average price of $122.52. Jazz Pharmaceuticals has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a market capitalization of $7.28 billion, a P/E ratio of 16.65, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the transaction, the chief executive officer now owns 440,307 shares in the company, valued at approximately $54,487,991.25. This trade represents a 0.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Neena M. Patil sold 3,800 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares of the company's stock, valued at $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,236 shares of company stock valued at $3,839,840. Company insiders own 4.20% of the company's stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. IFP Advisors Inc acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth about $25,000. Quadrant Capital Group LLC boosted its stake in Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 101 shares during the period. Elequin Capital LP grew its position in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after purchasing an additional 183 shares in the last quarter. CoreFirst Bank & Trust acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $28,000. Finally, Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at $29,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.